ACELYRIN, INC. to Join Upcoming Investor Conferences
ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharmaceutical company focused on speeding up the development and delivery of groundbreaking medicines in immunology, has announced its participation in several key investor conferences this September. Members of the management team will engage in fireside chats and hold one-on-one meetings to connect with potential investors and stakeholders.
Important Conferences in September
The company will take part in several major events, each offering a chance to discuss its innovative strategies and upcoming advancements.
Wells Fargo Healthcare Conference 2024
The Wells Fargo Healthcare Conference is scheduled for a Thursday. During this event, ACELYRIN team members will participate in a fireside chat from 1:30 PM to 2:05 PM ET. This session is expected to provide valuable insights into ACELYRIN's progress within the biopharmaceutical industry.
Morgan Stanley 22nd Annual Global Healthcare Conference
This conference will take place on a Friday, where ACELYRIN will be featured from 11:30 AM to 12:05 PM ET. The management team will discuss advancements and strategies aimed at successfully bringing their innovative therapies to market.
H.C. Wainwright 26th Annual Global Investment Conference
On another Monday afternoon, ACELYRIN will also participate in the H.C. Wainwright Conference. This presentation will take place from 2:00 PM to 2:30 PM ET, offering attendees insights into the company's ongoing projects and future initiatives.
Live Webcast Access
Live webcasts of these fireside chats will be available on the Company’s website in the Events & Presentations section. Additionally, replays of each webcast will be accessible for 30 days after the events, allowing investors to catch up on the latest updates and discussions.
About ACELYRIN, INC.
ACELYRIN, INC. is dedicated to providing transformative treatment options for patients by identifying, acquiring, and expediting the development and commercialization of innovative medicines. Their lead program, lonigutamab, is a monoclonal antibody administered subcutaneously, specifically targeting IGF-1R. It is currently being investigated for the treatment of thyroid eye disease, reflecting ACELYRIN’s commitment to introducing groundbreaking therapies to the market.
Contact Information
For further inquiries or more detailed information about their ongoing projects and business focus, please reach out to:
Tyler Marciniak
Vice President of Investor Relations and Corporate Affairs
investors@acelyrin.com
media@acelyrin.com
Frequently Asked Questions
What is the purpose of the investor conferences ACELYRIN is attending?
The conferences provide a platform for ACELYRIN’s management to connect with potential investors and stakeholders, sharing insights on new developments and future strategies.
What is ACELYRIN’s lead program?
ACELYRIN’s lead program, lonigutamab, is a monoclonal antibody that targets IGF-1R and is currently being investigated for the treatment of thyroid eye disease.
How can investors access the live webcasts?
Investors can watch the live webcasts on ACELYRIN’s website under the Events & Presentations section.
What are the dates of the conferences ACELYRIN will attend?
ACELYRIN will be participating in several conferences throughout September, including the Wells Fargo Healthcare Conference, the Morgan Stanley Global Healthcare Conference, and the H.C. Wainwright Global Investment Conference.
Who can I contact for more information about ACELYRIN?
For more information, you can contact Tyler Marciniak, the Vice President of Investor Relations and Corporate Affairs at ACELYRIN.
